The use of gabepentinoids in adults for chronic low back pain (CLBP) is limited due to substantial risk of adverse effects with no benefits on pain relief, according to a meta-analysis published in PLOS Medicine by Harsha Shanthanna from McMaster University, Canada, and colleagues.
‘Functional and emotional outcomes among patients taking gabapentinoids for chronic low back pain (CLBP) showed no significant improvements in pain.’
In 3 studies comparing gabapentin to placebo, gabapentin showed no significant improvement of pain; and in the 3 studies comparing pregabalin to other analgesics, pregabalin actually fared worse in pain relief.
There were no deaths or hospitalizations reported in any included studies of the drugs, but commonly reported adverse events included dizziness, fatigue, confusion, and visual disturbances. Functional and emotional outcomes among patients taking gabapentinoids for CLBP showed no significant improvements.
“Despite their widespread use, our systematic review with meta-analysis found that there are very few randomized controlled trials that have attempted to assess the benefit of using gabapentin or pregabalin in patients of chronic low back pain,” the authors say.
“The existing evidence does not support the use of gabapentinoids for predominant chronic low back pain, and calls for larger, high quality trials to more definitively inform this issue.”